Cefprozil side effects

List of side effects
Gastrointestinal Hepatobiliary Hypersensitivity CNS Hematopoietic Renal Other Cephalosporin class paragraph

Gastrointestinal
Diarrhea (2.9%), nausea (3.5%), vomiting (1%), and abdominal pain (1%). Return to top

Hepatobiliary
Elevations of AST (SGOT) (2%), ALT (SGPT) (2%), alkaline phosphatase (0.2%), and bilirubin values (<0.1%). As with some penicillins and some other cephalosporin antibiotics, cholestatic jaundice has been reported rarely. Return to top

Hypersensitivity
Rash (0.9%), urticaria (0.1%). Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy. Return to top

CNS
Dizziness (1%). Hyperactivity, headache, nervousness, insomnia, confusion, and somnolence have been reported rarely (<1%). All were reversible. Return to top

Hematopoietic
Decreased leukocyte count (0.2%), eosinophilia (2.3%). Return to top

Renal
Elevated BUN (0.1%), serum creatinine (0.1%). Return to top

Other
Diaper rash and superinfection (1.5%), genital pruritus and vaginitis (1.6%).

The following adverse events, regardless of established causal relationship to Cefprozil tablets, have been rarely reported during postmarketing surveillance: anaphylaxis, angioedema, colitis (including pseudomembranous colitis), erythema multiforme, fever, serum-sickness like reactions, Stevens-Johnson syndrome, and thrombocytopenia. Return to top

Cephalosporin class paragraph
In addition to the adverse reactions listed above which have been observed in patients treated with Cefprozil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: Aplastic anemia, hemolytic anemia, hemorrhage, renal dysfunction, toxic epidermal necrolysis, toxic nephropathy, prolonged prothrombin time, positive Coombs’ test, elevated LDH, pancytopenia, neutropenia, agranulocytosis. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. Return to top